首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

965965

口服糖尿病治療藥的全球市場(2020年～2027年)

Global Oral Anti Diabetes Drugs Market - 2021-2028

出版日期: 2021年08月06日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全貌
簡介
目錄

簡介

全球口服糖尿病治療藥市場成長，由於老年人口的增加，政府舉措的增加，及製藥企業的持續性研究開發等受到推動。

該市場的大幅度成長，是起因於糖尿病的盛行率的上升，及健康意識相關的各種醫療機關開始的計劃數增加等要素。現在，糖尿病病例整體約有10％是第一型，其餘是2型。第二型糖尿病的盛行率上升的話，對糖尿病治療藥有產生龐大需求的可能性。

但，口服糖尿病治療藥的高成本和替代解決方案的持續性妨礙市場成長。還有藥物費大幅度上升，胰島素的偏好，藥物相關的併發症等，預計抑制今後數年的市場擴大。

本報告提供全球口服糖尿病治療藥市場的相關調查，市場機會，成長及阻礙因素，COVID-19大流行的影響，各藥物類別、用途類型、流通管道、地區的市場分析，競爭情形，主要企業的簡介等資訊。

Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. Diabetes is of two types: type 1 and type 2. About 90% of people with diabetes have type 2 diabetes. Over the recent years, oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes.

Oral Anti Diabetes Drugs Market Dynamics

The global oral anti diabetes drugs market growth is driven by the growing geriatric population, rising government initiatives, and continuous research and development conducted by pharmaceutical manufacturers.

The rising prevalence of diabetes worldwide is likely to create a vast demand

The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. In 2019, it was estimated that out of 511 million people suffering from diabetes, 31.3% were undiagnosed. In 2019, diabetes was the cause of 4.2 million deaths per year, making it the eighth leading cause of death, worldwide. The diabetic condition, on the whole, doubles the risk of death. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2. Thus, the rise in the prevalence of type-2 diabetes worldwide is likely to create a vast demand for diabetes drugs..

Sedentary lifestyles & rise in cases of diabetes to leverage market revenue

Inactive lifestyle, obesity, and higher stress are anticipated to boost the demand for oral anti-diabetic drugs over the forecast period. Apart from this, technological breakthroughs and medical compensation facilities are likely to impel the growth of oral anti-diabetic drug market in the years ahead. Nevertheless, the increase in the R&D activities and tremendous potential for oral anti-diabetic drug market to grow will chart a profitable roadmap for the business over the forecast period, thereby normalizing the negative impact of hindrances on the oral anti-diabetic drug market

High cost of oral anti diabetes drugs and persence of alternate solution is hinder the market growth

However, the rise in the drug costs, is projected to restrict the expansion of oral anti-diabetic drug market in the forecast period. Also, preferred use of insulin over oral anti diabetes drugs and the complications associated with the drugs has been hindering the market growth.

COVID-19 Impact Analysis

Covid-19 pushes up sales of oral anti diabetes drugs. Patients given these drugs had a mortality rate of 18 percent as compared with 37 percent in matched patients receiving only insulin according to the study involved seven Italian hospitals during the first surge of COVID cases last spring. The pandemic is seems to impacting the operation of pharmaceutical companies with those dealing in oral anti diabetes drugs. Diabetics severely had turned people into buying more of medicines for these ailments. In the month of June, demand for Anti-Diabetic segment grew at 12.7 per cent yoy due to continued buying during the period of the lockdown. Thus, the pandemic has incresed the sale and ultimately growth of the oral anti diabetes drugs market in the forecast period.

Oral Anti Diabetes Drugs Market Segment Analysis

DPP-4 Inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

The Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors segment has the largest market share in the forecast period. DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure. Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs and as a monotherapy, thus, making it a widely used class of drugs. During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.

The sulfonylureas segment has the second largest market share in the forecast period. These are sometimes called "oral hypoglycemic agents," work very differently than metformin. They signal the pancreas to release insulin and they also help the body's cells use insulin better. Sulfonylureas may be old, but they're effective. They can lower A1C levels (a measure of blood sugar control over the previous 2-3 months) by 1% to 2%. The affordability and higher glucose-lowering efficacy are possible advantages that explain why this drug class is frequently used in practice. However, concerns have been raised for why sulfonylureas should not be used as first-line therapy, and should be avoided in use with metformin, due to concerns regarding severe cardiovascular and hypoglycemic risk.

Sulfonylureas are classified into two generations, first-generation and second-generation. Currently used are the second-generation sulfonylureas (Glyburide, Glipizide, Glimepiride, Glicazide), while the first-generation sulfonylureas are no longer used (Tolbutamide, Chlorpropamide, Tolazamide) due to severe hypoglycemia episodes. This drug class is typically used for patients with type 2 diabetes where cost is a major issue, patients who are not overweight, and for whom metformin is contraindicated, not well tolerated, or has failed to meet glycemic target goals. The most common adverse effects of sulfonylureas are hypoglycemia, weight gain, and risk for cardiovascular events. Clinicians initially prescribe lower doses of sulfonylureas to prevent the risks of hypoglycemia. Unfortunately, in some patients taking sulfonylureas, the adverse effects may outweigh the benefits.

Glicazide: Gliclazide is used in the treatment of type 2 diabetes mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is an antidiabetic medication. It works by increasing the amount of insulin released by the pancreas in order to lower the blood sugar levels. Gliclazide may also be called by the brand names Bilxona, Dacadis, Diamicron, Laaglyda, Nazdol, Vamju, Vitile, Ziclaseg and Zicron.

Glipizide: Glipizide is an oral diabetes medicine that helps control blood sugar levels by helping your pancreas produce insulin. Glipizide is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Glipizide oral tablet is available as the brand-name drugs Glucotrol and Glucotrol XL. It's also available as a generic drug. Generic drugs usually cost less. In some cases, they may not be available in every strength or form as the brand.

Glyburide : Glyburide oral tablet comes as brand-name drugs and as a generic drug. Brand names: Diabeta, Glynase PresTabs. Glyburide oral tablets come in two forms: regular and micronized. The micronized tablets contain smaller particles of the drug. Glyburide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes. Glyburide is in a class of medications called sulfonylureas. Glyburide lowers blood sugar by causing the pancreas to produce insulin.

Oral Anti Diabetes Drugs Market Geographical Analysis

North America region holds the largest market share global oral anti diabetes drugs market

North America region is dominating the global oral anti diabetes drugs market accounted for the largest market share in 2020, owing to the large investment in healthcare and pressing schedules and unhealthy eating habits of people, primarily in the U.S. is said to be driving the market in the region. In addition, growing sedentary lifestyle, presence of diabetes medicines in the Essential drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs in the region. Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drug market. The increasing incidence and prevalence of diabetes and the increasing healthcare expenditure in t countries are an indication of the increasing usage of oral anti-diabetes drugs.

Oral Anti Diabetes Drugs Market Competitive Landscape

The oral anti diabetes drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Glenmark Pharma, Abbott, Biocon, Sanofi, Sun pharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Piramal Healthcare, Bristol-Myers Squibb, Bayer Healthcare, Dr. Reddy's Laboratories Ltd, and Pfizer among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oral anti diabetes drugs market globally.

Oral Anti Diabetes Drugs Market Key Companies to Watch

Glenmark Pharma

Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Product Portfolio: The Company's portfolio comprised 164 products including of API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused in the areas of respiratory and dermatology.

Key Development: In April 2019, Glenmark Pharma launch of its anti-diabetes drug Remogliflozin in India. "Glenmark is the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin and India is the first country to get access to this innovative drug. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.

Why Purchase the Report?

Visualize the composition of the oral anti diabetes drugs market segmentation by drug class, dosage type, and distribution channel highlighting the key commercial assets and players.
Identify commercial opportunities in oral anti diabetes drugs market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of oral anti diabetes drugs market - level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players

The global oral anti diabetes drugs market report would provide an access to an approx. 65 market data table, 56 figures and 300 pages.

Target Audience

Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers

Market Segmentation

Global Oral Anti Diabetes Drugs Market - By Drug Class

DPP-4 Inhibitors
Sulfonylureas

Gliclazide

Glyburide

Glimepiride

Others

Meglitinides

Biguanides

Metformin

Repaglinide

Nateglinide

Others

Biguanides

Alpha-glycosidase inhibitors

Voglibose

Acarbose

Others

Other

Global Oral Anti Diabetes Drugs Market - By Dosage Type

Liquid
Capsule
Tablet

Global Monoclonal Antibody Therapeutics Market -By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Monoclonal Antibody Therapeutics Market - By Region

North America
South America
Europe
Asia
Middle East & Africa

1. Global Oral Anti Diabetes Drugs Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Global Oral Anti Diabetes Drugs Market - Market Definition and Overview

3. Global Oral Anti Diabetes Drugs Market - Executive Summary

3.1. Market Snippet by Drug Class
3.2. Market snippet by Dosage Type
3.3. Market Snippet by Distribution Channel
3.4. Market Snippet by Region

4. Global Oral Anti Diabetes Drugs Market - Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise In Cases Of Diabetes To Leverage Market Revenue
  - 4.1.1.2. Increasing obese population and changing lifestyle are the factors projected to boost market growth
- 4.1.2. Restraints:
  - 4.1.2.1. High cost of oral anti diabetes drugs
  - 4.1.2.2. Presence of alternate solution
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Global Oral Anti Diabetes Drugs Market - Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs

6. Global Oral Anti Diabetes Drugs Market - COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. Global Oral Anti Diabetes Drugs Market - By Drug Class

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
- 7.1.2. Market Attractiveness Index, By Drug Class Segment
7.2. DPP-4 Inhibitors *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Sulfonylureas
- 7.3.1. Gliclazide
- 7.3.2. Glyburide
- 7.3.3. Glimepiride
- 7.3.4. Others
7.4. Meglitinides
- 7.4.1. Biguanides
- 7.4.2. Metformin
- 7.4.3. Repaglinide
- 7.4.4. Nateglinide
- 7.4.5. Others
7.5. Biguanides
- 7.5.1. Alpha-glycosidase inhibitors
- 7.5.2. Voglibose
- 7.5.3. Acarbose
- 7.5.4. Others
7.6. Other

8. Global Oral Anti Diabetes Drugs Market - By Dosage Type

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Type
- 8.1.2. Market Attractiveness Index, By Dosage Type
8.2. Liquid*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Capsule
8.4. Tablet

9. Global Oral Anti Diabetes Drugs Market - By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
- 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Hospital Pharmacies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. Global Oral Anti Diabetes Drugs Market - By Region

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028 , By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Type
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Type
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Type
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Type
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Type
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Oral Anti Diabetes Drugs Market - Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of key companies to watch
11.5. List of the company with disruptive technology
11.6. List of start-up companies

12. Global Oral Anti Diabetes Drugs Market- Company Profiles

12.1. Glenmark Pharma*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Abbott
12.3. Biocon
12.4. Sanofi
12.5. Sunpharma
12.6. Novartis Novo Nordisk
12.7. Merck
12.8. GlaxoSmithKline
12.9. Piramal Healthcare
12.10. Bristol-Myers Squibb

LIST NOT EXHAUSTIVE